# Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod

> **NCT06356012** · PHASE4 · RECRUITING · sponsor: **Barretos Cancer Hospital** · enrollment: 96 (estimated)

## Conditions studied

- HSIL, High-Grade Squamous Intraepithelial Lesions
- Vaginal Microbiome
- Biomarkers

## Interventions

- **DRUG:** Imiquimod
- **PROCEDURE:** Loop Electrosurgical Excision Procedure

## Key facts

- **NCT ID:** NCT06356012
- **Lead sponsor:** Barretos Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-02
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-02-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06356012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06356012, "Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06356012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*